Abiopharma

🔍 Traub Robert T (Executive)

Company: QUAKER CHEMICAL CORP (KWR)

Report Date: 2026-03-15

Detailed Transactions and Holdings:

• Acquired 1,028 shares of Common Stock (Direct)
  Date: 2026-03-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,019.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 343 shares of Common Stock (Direct)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,362.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 534 shares of Common Stock (Direct)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,896.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 17 shares of Common Stock (Direct)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,913.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 562 shares of Common Stock at $118.45 per share (Direct)
  Date: 2026-03-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 4,351.00 | transaction_form_type: 4 | Footnotes: F4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-15 | Code: H | nature_of_ownership: By 401(k) | shares_owned_after: 1,262.00 | Footnotes: F5
• Sold 343 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 343.00 | transaction_form_type: 4 | Footnotes: F2, F6, F6
• Sold 534 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,069.00 | transaction_form_type: 4 | Footnotes: F2, F7, F7
• Sold 17 shares of Dividend Equivalent Rights (Derivative)
  Date: 2026-03-15 | Code: M | Expires: 2026-03-15 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F3, F3
• Acquired 1,772 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,772.00 | transaction_form_type: 4 | Footnotes: F8, F8, F8

Footnotes:

• F1: Shares earned upon vesting and settlement of Performance Stock Units (PSUs) awarded on March 15, 2023, upon certification of performance results by the Compensation and Human Resources Committee based on achievement of the adjusted return on invested capital (ROIC) metric, during the three year performance period.
• F2: Restricted stock units (RSUs) convert into common stock on a one-for-one basis.
• F3: Dividend equivalent rights (DERs) accrued on reporting person's RSUs granted on March 15, 2024 and March 15, 2025. The rights accrued when and as dividends were paid on KWR common stock. This Form 4 reports the settlement of DERs in connection with the second installment of the 2024 RSU grant and the first installment of the 2025 RSU grant, each vesting on March 15, 2026. Each DER was the economic equivalent of one share of KWR common stock.
• F4: Shares surrendered by reporting person to satisfy withholding tax obligation upon the full or partial vesting of certain restricted stock, PSUs, and RSUs previously granted under the Company's Long-Term Performance Incentive Plan.
• F5: Information based on reporting person's Plan Statement as of December 31, 2025.
• F6: On March 15, 2024, the reporting person was granted 1,029 time-based RSUs, vesting in three annual installments beginning on March 15, 2025.
• F7: On March 15, 2025, the reporting person was granted 1,603 time-based RSUs, vesting in three annual installments beginning on March 15, 2026.
• F8: Time-based RSUs granted under the Company's Long-Term Performance Incentive Plan, which will vest in three annual installments beginning on March 15, 2027. Each RSU represents a contingent right to receive one share of KWR common stock and DERs accrue with respect to these RSUs when and as dividends are paid on KWR common stock.